.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Healthtrust
UBS
Chubb
Cantor Fitzgerald
Fuji
Colorcon
Cerilliant
Julphar
Moodys

Generated: June 28, 2017

DrugPatentWatch Database Preview

Lomitapide mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lomitapide mesylate and what is the scope of lomitapide mesylate patent protection?

Lomitapide mesylate
is the generic ingredient in one branded drug marketed by Aegerion and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lomitapide mesylate has eighty-six patent family members in thirty-six countries.

There are two drug master file entries for lomitapide mesylate. One supplier is listed for this compound.

Summary for Generic Name: lomitapide mesylate

Tradenames:1
Patents:8
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list16
Clinical Trials: see list523
Patent Applications: see list3
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lomitapide mesylate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-003Dec 21, 2012RXYesNo7,932,268► Subscribe ► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-003Dec 21, 2012RXYesNo8,618,135► Subscribe ► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-005Apr 23, 2015RXYesNo9,265,758► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lomitapide mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-001Dec 21, 20125,739,135► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-003Dec 21, 20125,739,135► Subscribe
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-002Dec 21, 20125,739,135► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lomitapide mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,883,099 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
6,066,650 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
5,595,872 Nucleic acids encoding microsomal trigyceride transfer protein► Subscribe
5,789,197 Microsomal triglyceride transfer protein► Subscribe
6,034,098 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lomitapide mesylate

Country Document Number Estimated Expiration
South Africa9406772► Subscribe
European Patent Office0886637► Subscribe
Hungary218419► Subscribe
Portugal584446► Subscribe
South Korea20060129082► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LOMITAPIDE MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6 5001-2014Slovakia► SubscribePRODUCT NAME: LOMITAPID; REGISTRATION NO/DATE: EU/1/13/851/001 - EU/1/13/851/003 20130805
2014001Lithuania► SubscribePRODUCT NAME: LOMITAPIDUM; REGISTRATION NO/DATE: EU/1/13/851/001, 2013 07 31 EU/1/13/851/002, 2013 07 31 EU/1/13/851/003 20130731
0140001 00107Estonia► SubscribePRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013
00634Netherlands► SubscribePRODUCT NAME: LOMITAPIDE EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN, ZOALS DOOR HET BASISOCTROOI BESCHERMD; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
349Luxembourg► SubscribePRODUCT NAME: LOMITAPIDE ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130805
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Army
McKinsey
Fish and Richardson
Fuji
Novartis
Medtronic
Farmers Insurance
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot